Merck Provides Update on Keytruda (pembrolizumab) Indication in Third-Line Gastric Cancer in the US

KENILWORTH, N.J.--(BUSINESS WIRE) July 1, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company plans to voluntarily withdraw the U.S. accelera

Latest News Clinical News 887
Read All

James Ho, Founder of The CliniExpert Answered Questions of Reportes

Q:Would you give us a brief about CliniExpert? James Ho:Based in China, we are offering services to the global pharmaceutical research industry, esp. for the supply of the investigational product. We

Latest News Company Update 1243
Read All

In the "post-epidemic" era, How Can Chinese Clinical Comparators Save Your Cost ?

What is the "post-epidemic" era? My colleague Mr.Zhang once used to having noodles for lunch in the restaurant which is near the company for several years. But in 2020, this restaurant was c

Latest News Company Update 1461
Read All

First COVID-19 Variant Vaccine AZD2816 Phase II/III Trial Participants Vaccinated

27 June 2021 -- The first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 were vaccinated today to assess its safety and immunogenicity in both previously vaccinated

Latest News Clinical News 906
Read All

FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

WHIPPANY, N.J.-- July 9, 2021 (BUSINESS WIRE) -- Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved Kerendia (finerenone), a first-in-class nonsteroidal min

Latest News NDA News 1032
Read All

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

NEW BRUNSWICK, N.J., July 1, 2021 -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity again

Latest News Clinical News 859
Read All

Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine

GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publicat

Latest News Clinical News 833
Read All

Vaxzevria Induced Immunity for at Least One Year Following a Single Dose and Strong Immune Responses Following Either a Late Second Dose or a Third Dose

28 June 2021 -- A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or follow

Latest News Clinical News 898
Read All

Nirsevimab MEDLEY Phase II/III Trial Demonstrated Favourable Safety and Tolerability Profile in Infants at High Risk of RSV

28 June 2021 -- The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (R

Latest News Clinical News 956
Read All

FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombi

Latest News NDA News 804
Read All

FDA Approves Verkazia (cyclosporine ophthalmic emulsion) for the Treatment of Vernal Keratoconjunctivitis

EMERYVILLE, Calif.--(BUSINESS WIRE) June 24, 2021 -- Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on eye care, today

Latest News NDA News 1231
Read All

FDA Approves Astepro Allergy (azelastine) Nasal Spray for Over-the-Counter Use

WHIPPANY, N.J.--(BUSINESS WIRE) June 17, 2021 -- Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Astepro Allergy (Azelastine HCI .15%) as an over-the-counter (OTC)

Latest News NDA News 1664
Read All
News
- CLINIEXPERT -
Int'l Clinical Service Expert

We are the leader
Because of our professionism